The path to commercialization for a healthtech startup

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”4″ bottom_padding=”2″ overlay_alpha=”100″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ row_height_use_pixel=””][vc_column column_width_percent=”80″ gutter_size=”3″ style=”light” overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ zoom_width=”0″ zoom_height=”0″][vc_single_image media=”186″ media_width_percent=”100″][vc_column_text]In this episode of #DreamitLive, Healthtech Managing Director Adam Dakin speaks with Graftworx (Alio) founder and CEO David Kuraguntla about his startup’s path to commercialization. Graftworx (Alio) is a healthtech startup innovating the way remote patient monitoring is done, particularly for those with chronic conditions.[/vc_column_text][/vc_column][/vc_row]